Bajaj Healthcare gets license from DRDO to manufacture and market '2-Deoxy-D-Glucose'

08 Jul 2021 Evaluate

Bajaj Healthcare (BHL) has received a licence from Defence Research and Development Organisation (DRDO) to Manufacture and Market of 2-Deoxy-D-Glucose (2-DG) as approved medication for the treatment of COVID-19 patients. 2-Deoxy-D-Glucose (2-DG) helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence.

The drug works by selectively accumulating in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production. It can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe COVID-19 patients as an adjunct therapy to the existing standard of care.

Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.

Bajaj Healthcare Share Price

342.65 -4.40 (-1.27%)
01-Feb-2026 15:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1608.50
Dr. Reddys Lab 1171.50
Cipla 1321.55
Zydus Lifesciences 877.95
Lupin 2132.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×